Skip to main content

letter

. 1996 Jan 27;312(7025):252. doi: 10.1136/bmj.312.7025.252a

Increasing prescription of drugs for secondary prevention of myocardial infarction. Authors' recommendations are too restrictive.

R J Sapsford, M B Robinson, A S Hall

PMCID: PMC2350041 PMID: 8563612

252

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Hall A. S., Winter C., Bogle S. M., Mackintosh A. F., Murray G. D., Ball S. G. The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. J Cardiovasc Pharmacol. 1991;18 (Suppl 2):S105–S109. [PubMed] [Google Scholar]
Køber L., Torp-Pedersen C., Carlsen J. E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D. S., Auclert L., Pauly N. C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995 Dec 21;333(25):1670–1676. doi: 10.1056/NEJM199512213332503. [DOI] [PubMed] [Google Scholar]
Smith J., Channer K. S. Increasing prescription of drugs for secondary prevention after myocardial infarction. BMJ. 1995 Oct 7;311(7010):917–918. doi: 10.1136/bmj.311.7010.917. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES